ASH: Marstacimab Phase III data show significant bleed reduction in hemophilia A and B

Findings from the pivotal Phase III BASIS clinical trial evaluating marstacimab for the treatment of people with severe hemophilia A and moderately severe to severe hemophilia B without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) were released at the American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego.

The drug’s developer, US pharma giant Pfizer (NYSE: PFE), said the results from the BASIS trial demonstrated a statistically-significant and clinically-meaningful effect on annualized bleeding rate (ABR).

“For more than five decades, the most common treatment for hemophilia A and B has been intravenous infusions that are often administered multiples times per week,” said Dr James Rusnak, senior vice president, chief development officer, internal medicine and infectious diseases, R&D at Pfizer. “Based on these results and if approved, we believe marstacimab could offer a subcutaneous option with a compelling combination of efficacy and safety that may significantly reduce the risk of bleeding. We look forward to potentially bringing this treatment option to people living with hemophilia A and B without inhibitors.”